Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer

BACKGROUND: To compare the efficacy and toxicity of peptide-doxorubicin (PDOX) and doxorubicin (DOX) on nude mice models of human gastric cancer. RESULTS: Both PDOX and DOX could significantly inhibit tumor growth compared with Control (P < 0.05) in both subcutaneous and orthotopic models. Animal...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jue, Yuan, Jing-Ping, Wang, Qun, Shao, Li-Hua, Liu, Shao-Ping, Firestone, Raymond A., Hong, Ya-Ping, Li, Ji-Guo, Xin, Yan-Chao, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788612/
https://www.ncbi.nlm.nih.gov/pubmed/29416744
http://dx.doi.org/10.18632/oncotarget.23319
_version_ 1783296106520641536
author Zhang, Jue
Yuan, Jing-Ping
Wang, Qun
Shao, Li-Hua
Liu, Shao-Ping
Firestone, Raymond A.
Hong, Ya-Ping
Li, Ji-Guo
Xin, Yan-Chao
Li, Yan
author_facet Zhang, Jue
Yuan, Jing-Ping
Wang, Qun
Shao, Li-Hua
Liu, Shao-Ping
Firestone, Raymond A.
Hong, Ya-Ping
Li, Ji-Guo
Xin, Yan-Chao
Li, Yan
author_sort Zhang, Jue
collection PubMed
description BACKGROUND: To compare the efficacy and toxicity of peptide-doxorubicin (PDOX) and doxorubicin (DOX) on nude mice models of human gastric cancer. RESULTS: Both PDOX and DOX could significantly inhibit tumor growth compared with Control (P < 0.05) in both subcutaneous and orthotopic models. Animal survival was much better in PDOX group than DOX group. In peripheral blood test, PDOX group had significantly higher levels of platelets than the Control (P < 0.05), and lymphocyte lower than Control (P < 0.05). There were no significant differences on liver, kidney and cardiac function parameters among three groups (P > 0.05). Immunohistochemistry showed that treatment groups had much higher Tunel than Control (P < 0.05), and PDOX had significantly lower Ki-67 than doxorubicin and Control group (P < 0.01). Western blotting showed that PDOX caused much higher expressions of P53, P21, Aparf-1, pro- and cleaved-caspase 3, compared with DOX. CONCLUSION: Compared with DOX, PDOX has increased effects but much decreased toxicity in treating animal model of gastric cancer. MATERIALS AND METHODS: Animals in subcutaneous model were randomized into Control, doxorubicin, PDOX-L, PDOX-M, and PDOX-H groups. Animals in surgical orthotopic implantation model were randomized into Control, doxorubicin and, peptide-doxorubicin groups. The animals were treated, monitored and examined following a set protocol.
format Online
Article
Text
id pubmed-5788612
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57886122018-02-07 Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer Zhang, Jue Yuan, Jing-Ping Wang, Qun Shao, Li-Hua Liu, Shao-Ping Firestone, Raymond A. Hong, Ya-Ping Li, Ji-Guo Xin, Yan-Chao Li, Yan Oncotarget Research Paper BACKGROUND: To compare the efficacy and toxicity of peptide-doxorubicin (PDOX) and doxorubicin (DOX) on nude mice models of human gastric cancer. RESULTS: Both PDOX and DOX could significantly inhibit tumor growth compared with Control (P < 0.05) in both subcutaneous and orthotopic models. Animal survival was much better in PDOX group than DOX group. In peripheral blood test, PDOX group had significantly higher levels of platelets than the Control (P < 0.05), and lymphocyte lower than Control (P < 0.05). There were no significant differences on liver, kidney and cardiac function parameters among three groups (P > 0.05). Immunohistochemistry showed that treatment groups had much higher Tunel than Control (P < 0.05), and PDOX had significantly lower Ki-67 than doxorubicin and Control group (P < 0.01). Western blotting showed that PDOX caused much higher expressions of P53, P21, Aparf-1, pro- and cleaved-caspase 3, compared with DOX. CONCLUSION: Compared with DOX, PDOX has increased effects but much decreased toxicity in treating animal model of gastric cancer. MATERIALS AND METHODS: Animals in subcutaneous model were randomized into Control, doxorubicin, PDOX-L, PDOX-M, and PDOX-H groups. Animals in surgical orthotopic implantation model were randomized into Control, doxorubicin and, peptide-doxorubicin groups. The animals were treated, monitored and examined following a set protocol. Impact Journals LLC 2017-12-14 /pmc/articles/PMC5788612/ /pubmed/29416744 http://dx.doi.org/10.18632/oncotarget.23319 Text en Copyright: © 2018 Zhang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zhang, Jue
Yuan, Jing-Ping
Wang, Qun
Shao, Li-Hua
Liu, Shao-Ping
Firestone, Raymond A.
Hong, Ya-Ping
Li, Ji-Guo
Xin, Yan-Chao
Li, Yan
Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer
title Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer
title_full Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer
title_fullStr Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer
title_full_unstemmed Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer
title_short Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer
title_sort experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788612/
https://www.ncbi.nlm.nih.gov/pubmed/29416744
http://dx.doi.org/10.18632/oncotarget.23319
work_keys_str_mv AT zhangjue experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer
AT yuanjingping experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer
AT wangqun experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer
AT shaolihua experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer
AT liushaoping experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer
AT firestoneraymonda experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer
AT hongyaping experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer
AT lijiguo experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer
AT xinyanchao experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer
AT liyan experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer